Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Recurrence of esophageal intestinal metaplasia after treatment of Barrett's

This month's issue of Gastroenterology examines the recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus.

News image

Radiofrequency ablation is an established treatment for dysplastic Barrett's esophagus.

Although short-term end points of ablation have been ascertained, there have been concerns about recurrence of intestinal metaplasia after ablation.

Dr Milli Gupta and colleagues from Minnesota, USA estimated the incidence and identified factors that predicted the recurrence of  intestinal metaplasia  after successful radiofrequency ablation.

The researchers analyzed data from 592 patients with Barrett's esophagus treated with radiofrequency ablation from 2003 through 2011 at 3 tertiary referral centers.

The doctors defined complete remission of intestinal metaplasia as eradication of intestinal metaplasia, documented by 2 consecutive endoscopies.

Recurrence was defined as the presence of intestinal metaplasia or dysplasia after complete remission of intestinal metaplasia  in surveillance biopsies.

There were 2 experienced gastrointestinal pathologists that confirmed pathology findings.

The doctors noted that based on histology analysis, before radiofrequency ablation, 71% of patients had high-grade dysplasia or esophageal adenocarcinoma, 15% had low-grade dysplasia, and 14% had nondysplastic Barrett's esophagus.

Of patients treated, 448 were assessed after radiofrequency ablation.

There were 55% of patients who underwent endoscopic mucosal resection before radiofrequency ablation.

22% of all recurrences observed were dysplastic Barrett's esophagus
Gastroenterology

The researchers found that the median time to complete remission of intestinal metaplasia  was 22 months, with 56% of patients in complete remission of intestinal metaplasia  by 24 months.

Increasing age and length of Barrett's esophagus segment were associated with longer times to complete remission of intestinal metaplasia.

The team noted that 24 months after complete remission of intestinal metaplasia, the incidence of recurrence was 33%.

The researchers found that 22% of all recurrences observed were dysplastic Barrett's esophagus.

The doctors noted that there were no demographic or endoscopic factors associated with recurrence.

Complications developed in 6.5% of subjects treated with radiofrequency ablation, and strictures were the most common complication.

Dr Gupta's team commented, "Of patients with Barrett's esophagus treated by radiofrequency ablation , 56% were in complete remission after 24 months."

"However, 33% of these patients had disease recurrence within the next 2 years."

"Most recurrences were nondysplastic and endoscopically manageable, but continued surveillance after Radiofrequency ablation is essential."

Gastroenterol 2013: 145(1): 79-86
12 July 2013

Go to top of page Email this page Email this page to a colleague

 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Fibre for chronic idiopathic constipation
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care
 01 June 2016 
Predicting NASH resolution
 01 June 2016 
Predicting relapse in IBD
 01 June 2016 
Treatment of Hep C/HIV after liver transplant
 31 May 2016 
Markers as a reflection of inflammatory burden in ulcerative colitis
 31 May 2016 
Predicting Crohn's diseases before diagnosis
 31 May 2016 
Biomarker predicts post ERCP pancreatitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us